



BULK DRUG MANUFACTURES ASSOCIATION (INDIA)

C-25, INDUSTRIAL ESTATE, SANATHNAGAR, HYDERABAD, TELANGANA-500018

Email: ed@bdmai.org, info@bdmai.org Ph:040-23706718/4804

Circular No. BDMA/050/2026

Date:6th Feb 2026

Dear Sir

Sub: Scheme for promotion of Domestic Production of Fermentation based Bulk Drugs – Inputs required for Department of Pharmaceuticals

We received a communication from the Department of Pharmaceuticals informing that the Department is proposing to design a Scheme to promote domestic production of Fermentation based Bulk Drugs along with critical building blocks such as amino acids and nucleotides etc. Copy of the communication received along with a list of products identified by them is attached herewith for information.

For this purpose, the Department would like to reach out to those companies who are interested in manufacturing these products to understand the complexities of manufacturing these products, present domestic capacities, level of required investments etc. This helps the Department to design an appropriate scheme to promote domestic production of these products.

We, therefore, request the members who are interested in manufacturing these products may please inform us by providing following data:

Sl. No.	Name of the Company with address	Products interested in manufacturing	Present production capabilities	Contact Details		
				Name of the person & Designation	e-mail	Mobile

Interested members are requested to provide the above data to ed@bdmai.org; info@bdmai.org; before 10th February 2026 to enable BDMAI to compile and submit to the Department.

With regards

M Roja Rani
Executive Director

ANNEXURE A

I. Antibiotics

- **Cephalosporin precursors:** 7-ACA, D-7-ACA, mica ester/side chains (and downstream products)
- **Aminoglycosides:** streptomycin, neomycin, tobramycin, kanamycin, gentamicin, amikacin, netilmicin
- **Glycopeptides:** vancomycin, teicoplanin, dalbavancin, telavancin
- **Lincosamides:** Lincomycin → derivatives like clindamycin phosphate/palmitate
- **Tetracycline family:** chlortetracycline, tetracycline, oxytetracycline, doxycycline, minocycline, tigecycline, etc.

II. Antifungal

- **Echinocandins:** caspofungin, micafungin, anidulafungin, etc. (typically made from fermentation-derived precursors)

III. Fermentation-based vitamins

- Vitamin **B12, C, E, B1**, etc.

IV. Not typically considered “fermentation-based drugs” here:

- **I. Nucleotides** (adenine, cytosine, guanine)
- **II. Amino acids** (these are fermentation products industrially, but they're usually considered as chemical Bulk Drugs)
 - **Shikimic acid and Chorismate derivatives:** L- Phenyl Alanine, L-Tyrosene, L-Tryptophan
 - **Aspartate and related aminoacids:** Lycine, Methionine, Threonine, Isoleucine, Asparagine.

सत्यप्रकाश टी.एल., मा.प्र.से.
संयुक्त सचिव
Satyaprakash T.L., I.A.S.
Joint Secretary



भारत सरकार
रसायन और उर्वरक मंत्रालय
औषध विभाग
Government of India
Ministry of Chemicals & Fertilizers
Department of Pharmaceuticals

D.O. No. 009/JS(STL)-2025

Dated 2nd February, 2026

Dear Sir

Subject: Request for industry inputs for designing a scheme to promote manufacture of fermentation-based bulk drugs

As you are aware, the Union Budget 2026 has placed emphasis on capacity development, with Pharmaceuticals identified as one of the key sectors for such development. In this context, fermentation-based bulk drugs—along with critical building blocks such as amino acids and nucleotides—are recognized as essential constituents of India's pharmaceutical security.

2. I am directed to request the Industry Associations and other stakeholders vis-à-vis Pharmaceutical Industry to provide comments and suggestions to support the Department in designing an appropriate scheme to promote domestic manufacturing of fermentation-based bulk drugs.

3. A list of select fermentation-based bulk drugs, along with amino acids, nucleotides and vitamins, is enclosed at **Annexure A** for your kind reference. In this regard, you are **requested to share details of industries/entities that may be interested in manufacturing these products, along with their particulars (such as company name, location, proposed products, current capabilities, and contact details)**. The Department intends to reach out to such entities for further consultations.

4. Stakeholders are also requested to:

- Suggest any additional fermentation-based bulk drugs/building blocks that merit inclusion in the proposed scheme; and
- Provide inputs on preferred/viable business models for adoption under the scheme.

5. Your feedback will assist the Department in designing the scheme in an optimal and judicious manner. It is also felt that, instead of supporting isolated individual products, it may be more efficient and impactful to support **platform-based manufacturing**. For instance, rather than supporting only tetracycline, support could be structured for the broader "cycline" antibiotic platform such as chlortetracycline, tetracycline, oxytetracycline, doxycycline, minocycline, and allied products based on the naphthacene core.

..contd 2/-

शास्त्री भवन, डॉ राजेन्द्र प्रसाद मार्ग, नई दिल्ली - 110 001
Shastri Bhawan, Dr. Rajendra Prasad Road, New Delhi - 110 001
Tel : 011-23385131 | Email : js1-pharma@gov.in

: page 2:

6. I will be grateful if you can provide information at the earliest. You may consider to mail the information to following address:

Name	Designation	Email I'd
Shri Satyaprakash TL	Joint Secretary	head-pharmapolicy@pharma-dept.gov.in
Shri Suvasis Das	Deputy Secretary	ds-pharmapolicy@pharma-dept.gov.in
Shri Suhas Bhuyan	Under Secretary	us-pharmaschemes@pharma-dept.gov.in

Best Wishes .

Yours sincerely,


2.02.2026.
(Satyaprakash TL)

To all Industry Associations and other stakeholders